Clinical

Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment.

At the 2023 Greater Philadelphia Business Coalition on Health, panelists described the ways their organizations are promoting access to primary care in hopes that it can be part of the progress toward achieving the Quadruple Aim of lower costs, better outcomes, patient satisfaction, and clinician experience.

Cytokine release syndrome can limit aggressive RRMM treatment strategies.

Panelists discuss relapsed/refractory multiple myeloma treatment regimen strategies.

A symposium at the 2023 American Thoracic Society (ATS) International Conference featured research on predictors of chronic obstructive pulmonary disease (COPD) occurrence and disease progression.

The panel measures the significance of an RSV vaccine in relation to other vaccines in circulation.

Traditionally thought of as a pediatric disease, RSV also affects older patient populations.

Posters presented at the 2023 American Thoracic Society International Conference called for improvements in care for chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shared his thoughts on the most important recent advances in non–small cell lung cancer (NSCLC), including a better understanding of patients who may benefit from immunotherapy.

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo.

Although the condition is rare and cases are limited, researchers were able to generally conclude vagal nerve stimulation (VNS) serves as a well-tolerated intervention.

Gene therapies like RGX-314 are looking to treat very common diseases in ophthalmology, which would represent a tremendous opportunity for chronic disease management, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.

This article describes the approach that a large primary care group at risk for value-based payments chose to deploy in managing clinical and financial outcomes of knee osteoarthritis jointly with orthopedic surgeons.

A recent study suggests that monitoring anxiety and distress levels during watch-and-wait disease management time frames may improve the patient experience.

Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Soyini Hawkins, MD, MPH, FACOG, drives a conversation regarding the impact of race in diagnosing endometriosis.

Early detection of uterine fibroids and endometriosis has been powered by the Affordable Care Act, ultimately improving prognosis for patient outcomes.

Pulmonary arterial hypertension (PAH) is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process.

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.